SOURCE: iSatori

iSatori

September 09, 2014 12:37 ET

iSatori Launches Its Newest Patented Weight-Loss Pill -- Sinetrim™ With Sinetrol® -- Under the BioGenetics Brand to Retail Stores Nationwide

GOLDEN, CO--(Marketwired - Sep 9, 2014) - iSatori, Inc. (OTCQB: IFIT), today announced the launch of their newest weight-loss innovation, called Sinetrim™, featuring patented Sinetrol®, nationally with America's largest retailer of specialty supplements, GNC (www.GNC.com), and the largest domestic distributor of sports nutrition supplements, Europa Sports (www.europasports.com).

With numerous top-selling diet support supplements scientifically engineered and already in retail by its Biogenetic Laboratories division (including Garcinia Trim™, MeraTrim® Platinum+, and hCG Activator™), iSatori expects Sinetrim™ to be well received by distributors, retailers, and consumers alike, especially due to the robust scientific support for the patented Sinetrol® ingredient.

"There are over 65 million dieters in America, so we remain committed with our BioGenetic Laboratories' branded products to address this serious need by consumers. What we found most interesting about Sinetrol®, in addition to the exciting initial research indicating positive weight-loss results, is how well it ties in with the popular Mediterranean Diet," noted Stephen Adele, Founder and Chief Executive Officer of iSatori, Inc. (www.isatori.com).

Sinetrim™ is the first to launch Sinetrol® as a patented synergistic blend of polyphenolic compounds derived from Mediterranean citrus fruits. "The basis for our research included two well-documented, peer-reviewed clinical studies documenting its profound weight-loss effects. One study, in particular, showed it helped participants reduce abdominal fat by up to 9.73% and reduce inches off the hips and waists, both of which are considered problem areas for many people struggling to lose weight," added Adele.

iSatori began shipping Sinetrim™ to retailers in August, and the product is now available nationwide at GNC stores (and online at GNC.com), the world's largest specialty supplement retailer, with over 6,000 stores in the U.S. and locations in 49 other countries. Sinetrim™ with patented Sinetrol® is also exclusively available through Europa Sports, the nation's largest sports and health nutrition wholesale distributor, which supplies over 14,000 specialty and independent retailers, along with the rest of the BioGenetic Laboratories weight-loss products line.

Consumers interested in finding out more about Sinetrim™ with Sinetrol® are directed to the Biogenetic Laboratories website at www.BioGeneticLabs.com, or they can order direct by calling 1-888-752-6615. Those seeking weight-loss education and support, and additional product information on Sinetrim™ with Sinetrol®, should visit their social community support site at http://www.facebook.com/BiogeneticLabs.

Retailers interested in carrying Sinetrim™ with Sinetrol® can contact Europa Sports at 1-800-447-4795 or visit http://www.EuropaSports.com.

About iSatori, Inc.
iSatori is a consumer products firm that develops and sells scientifically engineered nutritional products through online marketing, Fortune 500 retailers, and thousands of retail stores around the world. The Company is headquartered in Golden, Colorado, and its common stock trades on the OTCQB under the symbol "IFIT." More information about the Company is available at http://www.isatori.com.

Forward-Looking Statements
Statements made in this news release relating to the Company's future sales, expenses, revenue, product developments, and all other statements except statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We have used the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "should," "will," "potential," and similar terms and phrases to identify forward-looking statements in this press release. These statements are based on assumptions and estimates that management believes are reasonable based on currently available information; however, management's assumptions and the Company's future performance are both subject to a wide range of business risks and uncertainties, and there is no assurance that these goals and projections can or will be met. Any number of factors could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to, the timing and extent of changes in demand for the Company's products, the availability and price of ingredients necessary to manufacture such products, and the outcome of any current or future litigation regarding such products or similar products of competitors. Please see our Risk Factor disclosures included in our Registration Statement on Form S-1, as amended, initially filed with the Securities and Exchange Commission on April 30, 2013, and in subsequent filings with the Securities and Exchange Commission. All future written or oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. The forward-looking statements herein speak as of the date of this press release. We undertake no obligation to update any information contained herein or to publicly release the results of any revisions to any forward-looking statements that may be made to reflect events or circumstances that occur, or that we become aware of, after the date of this press release.